As of March 12, 2019 the U.S. FDA approved a new generic of Diovan (valsartan) for high blood pressure and heart failure to relieve the shortage from multiple recalls of generic valsartan products from several manufacturers. The approval of the new generic of Diovan was granted to Alkem Laboratories Limited.
Certain lots of valsartan and other ARB medicines were found to contain nitrosamine impurities, causing the shortage. Information about recalls can be found here.
Read the full FDA press release here.